NEW YORK (GenomeWeb) – Leerink today downgraded Foundation Medicine's shares following Roche's announcement that it will acquire a majority stake in the cancer genomics diagnostics firm. 

Analyst Dan Leonard downgraded Foundation to Market Perform from a previous Outperform rating, while he raised the target price on the company's shares to $50 from $30. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.